Phio Pharmaceuticals Corp. to Hold Virtual Non-Transactional Roadshow

Summary

Phio Pharmaceuticals Corp. will participate in a virtual non-deal roadshow on June 30, 2025, at 10:00 AM Eastern Time. CEO Robert Bitterman will present the latest advances in the company’s INTASYL® gene silencing technology and the progress of the PH-762 Phase 1b clinical trial for skin cancer treatment, which has shown positive interim results. Stakeholders and investors are invited to attend the event to learn about Phio’s innovative cancer therapies.

Impact Analysis

The event is classified at the company level, as it specifically concerns Phio Pharmaceuticals Corp. The announcement of the virtual roadshow and the positive interim results of the PH-762 clinical trial are likely to influence investor sentiment positively and potentially increase the company’s stock price. First-order effects include heightened interest from investors and stakeholders in Phio’s stock, particularly those focused on cancer treatment developments. Second-order effects may involve increased attention from biotech industry analysts, leading to potential strategic partnerships or collaborations. Investment opportunities include considering Phio Pharmaceuticals Corp.'s stock for potential growth, given its focus on innovative cancer therapies. However, investors should also consider risks related to clinical trial outcomes and regulatory approvals.